The Scientific Program - Epilepsy
|
Thursday, April 04, 2019 |
|
Hall A-CAJAL |
|
|
13:45-15:15 |
SESSION 3 | PLENARY LECTURES: EPILEPSY |
||
|
Chairpersons: |
Mar Carreno, Spain & Vladimir Donath, Slovakia |
||
|
13:45-14:15 |
Epilepsy genetics and precision therapies – trials and tribulations: Samuel Berkovic, Australia |
||
|
14:15-14:45 |
Gene therapy in epilepsy: Matthew Walker, UK |
||
|
14:45-15:15 |
How will new devices impact the diagnosis and treatment of seizures? Michael Sperling, USA |
||
|
15:15-15:30 |
Coffee Break |
||
|
Friday, April 05, 2019 |
|
Hall B-PICASSO |
|
|
07:30-08:30
|
Chairpersons: Zaid Afawi, Israel
FREE COMMUNICATIONS, EPILEPSY & PME
Overlap of the pitt – Hopkins and Lennox-Gastaut syndromes: Biljana Dapic Ivancic, Croatia
Prevalence of headache among patients with epilepsy: Ewa Czapińska-Ciepiela, Poland
|
||
|
08:30-10:10 |
SESSION 9 | IMMUNE THERAPY IN EPILEPSY; NON EPILEPTIC SEIZURES: PSYCHOGENIC OR NOT? |
||
|
Chairpersons: |
Nandan Yardi, India & Juan José Poza, Spain |
||
|
08:30-09:20 |
Should we routinely prescribe immune modulatory therapy to patients with refractory adult-onset epilepsy who also develop psychiatric or cognitive impairment? |
||
|
|
Capsule: Autoimmune epilepsy is often accompanied by cognitive, behavioral, psychiatric or motor symptoms. However, such symptoms are often present in epilepsy patients without an autoimmune cause. Diagnosis of an autoimmune disease may be challenging.Should autoimmune treatment be initiated in people without known antibodies who have accompanying symptoms? |
||
|
08:30-08:40 |
Host: Dana Ekstein, Israel |
||
|
08:40-08:55 |
Pro: William Theodore, USA |
||
|
08:55-09:10 |
Con: Martin Holtkamp, Germany |
||
|
09:10-09:20 |
Discussion and rebuttals |
||
|
|
|
||
|
09:20-10:10 |
Are non-epileptic seizures really psychogenic? |
||
|
|
Capsule: A variety of non-epileptic behaviors may be misdiagnosed as epileptic seizures. Many are deemed psychogenic in nature, particularly when co-existing psychiatric morbidity is present. Is the presumption of a psychogenic cause supported by evidence? |
||
|
09:20-09:30 |
Host: Alla Guekht, Russia |
||
|
09:30-09:45 |
Pro: Curt W LaFrance, USA |
||
|
09:45-10:00 |
Con: Amos Korczyn, Israel |
||
|
10:00-10:10 |
Discussion and rebuttals |
||
|
10:10-10:25 |
Coffee Break |
||
|
10:25-12:05 |
SESSION 10 | EPILEPSY: TREATMENT OF RESISTANT SEIZURES |
||
|
Chairpersons: |
Arie Weinstock, USA & Nana Tatishvili, Georgia |
||
|
10:25-11:15 |
Should antiepileptic drugs be pushed to high doses and levels before switching to or adding a new drug? |
||
|
|
Capsule: Traditional practice has been to raise doses of antiepileptic medication to achieve relatively high levels before switching to or adding another agent. Is this practice appropriate, or is failure at low dose indicative of treatment failure? |
||
|
10:25-10:35 |
Host: Manuel Toledo, Spain |
||
|
10:35-10:50 |
Pro: Elinor Ben-Menachem, Sweden |
||
|
10:50-11:05 |
Con: Martin Brodie, UK |
||
|
11:05-11:15 |
Discussion and rebuttals |
||
|
|
|
||
|
11:15-12:05 |
Should vagus nerve stimulation (VNS) be recommended early in the course of illness when seizures fail to respond to medication and cause falling or generalize? |
||
|
|
Capsule: VNS has the potential to moderately reduce seizure frequency. Should early use be advised primarily for patients whose seizures may cause injury, or should VNS be more broadly applied? What benefits would be expected in either situation – do patients with non-injurious seizures gain sufficiently to warrant treatment? |
||
|
11:15-11:25 |
Host: Zeljka Petelin Gadze, Croatia |
||
|
11:25-11:40 |
Pro: Antonio Gil-Nagel, Spain |
||
|
11:40-11:55 |
Con: Ivan Rektor, Czech Republic |
||
|
11:55-12:05 |
Discussion and rebuttals |
||
|
13:05-14:15 |
Lunch Break |
||
|
13:15-:14:15 |
Meet the Expert – Epilepsy (Lafora) |
||
|
|
Spotlight on the antiepileptic drug eslicarbazepine acetate: sharing experience from clinical practice: Vicente Villanueva, Spain |
||
|
14:15-15:45 |
SESSION 11 | LACTATION IN EPILEPSY; CANNABIS? |
||
|
Chairpersons: |
Andry Dubenko, Ukraine & Xiana Rodríguez Osorio, Spain |
||
|
14:15-14:55 |
Should women breastfeed if they take anticonvulsant medication? |
||
|
|
Capsule: Breastfeeding is generally recommended as a healthy practice. However, antiepileptic drugs are delivered to babies via breast milk. Is breastfeeding a sensible and safe practice for a baby whose mother takes an antiepileptic drug? |
||
|
14:15-14:25 |
Host: Ilan Blatt, Israel |
||
|
14:25-14:35 |
Yes: Martin Brodie, UK |
||
|
14:35-14:45 |
No: Alla Guekht, Russia |
||
|
14:45-14:55 |
Discussion and rebuttals |
||
|
|
|
||
|
14:55-15:45 |
Should we prescribe medical marijuana for adult patients with drug-resistant epilepsy? |
||
|
|
Capsule: Some chemical constituents of marijuana may have anti-seizure effects, and Dravet and Lennox-Gastaut syndromes respond to cannabidiol. Do we know enough about medical marijuana to advise its use in adults with refractory epilepsy? |
||
|
14:55-15:05 |
Host: Martin Holtkamp, Germany |
||
|
15:05-15:20 |
Yes: Elson So, USA |
||
|
15:20-15:35 |
No: Ilan Blatt, Israel |
||
|
15:35-15:45 |
Discussion and rebuttals |
||
|
15:45-16:00 |
Coffee Break |
||
|
16:00-19:00 |
SESSION 12 | EPILEPSY: ADVANCED MRI; GENETICS |
||
|
Chairpersons: |
Tetyana Litovchenko Ukraine |
||
|
16:00-16:50 |
Are genetic data likely to be of major importance in the personalized treatment of epilepsy patients? |
||
|
|
Capsule: In addition to being causative in some rare epilepsies, genetic variants may play a role in susceptibility to more common types of epilepsy. Can these genetic features be used to guide management in individual patients? |
||
|
16:00-16:10 |
Host: Michael Sperling, USA |
||
|
16:10-16:25 |
Likely: Samuel Berkovic, Australia |
||
|
16:25-16:40 |
Unlikely: William Theodore, USA |
||
|
16:40-16:50 |
Discussion and rebuttals |
||
|
|
|
||
|
16:50-17:40 |
Should MRI scans undergo routine post-processing if visual inspection is normal in people with epilepsy? |
||
|
|
Capsule: A variety of sophisticated computer techniques can be employed in the analysis of MRI scans. When visual inspection fails to reveal an abnormality, do these techniques improve diagnosis, and is their use worthwhile? |
||
|
16:50-17:00 |
Host: Manuel Toledo, Spain |
||
|
17:00-17:15 |
Yes: Matthias Koepp, UK |
||
|
17:15-17:30 |
No: Elson So, USA |
||
|
17:30-17:40 |
Discussion and rebuttals |
||
|
17:40-19:00 |
Epilepsy Cases, Michael Sperling, USA, and Manjari Tripathi, India Capsule: Challenging cases will be presented to participants for discussion |
||
|
END OF FRIDAY HALL B- PICASSO |
|||
|
Saturday, April 06, 2019 |
|
Hall C- DE FALLA |
|
|
07:00-08:00 |
E-Poster Presentations |
||
|
08:00-10:40 |
SESSION 32 | PROGRESSIVE MYOCLONUS EPILEPSIES (PME) |
||
|
Chairpersons: |
Rimma Gamirova, Russia |
||
|
|
Capsule: PME's are rare, but very challenging epilepsies to manage. The majority of cases can now be given a specific diagnosis, and new disorders have been recently described. Here we will discuss the diagnostic approach, insights from the new genetics, treatment with conventional anti-epileptic drugs and emerging precision therapies. |
||
|
08:00-08:05 |
Welcome, introduction, learning objectives: Jose Serratosa, Spain |
||
|
08:05-08:35 |
PMEs: Clinical diagnosis, new forms and epilepsies on the borderland: Samuel Berkovic, Australia |
||
|
08:35-09:05 |
Emerging treatments for the treatment of PME: Pasquale Striano, Italy |
||
|
09:05-09:35 |
Enzyme replacement therapy for CLN2: Marina Trivisano, Italy |
||
|
09:35-10:05 |
Lafora disease: Neurobiology and new therapeutic strategies: Jose Serratosa, Spain |
||
|
10:05-10:30 |
Management of MERRF patients including myoclonic epilepsy: Josef Finsterer, Austria |
||
